logo
World No Tobacco Day 2025: Experts Unite Against Tobacco as a Leading Cause of Cancer and Chronic Diseases

World No Tobacco Day 2025: Experts Unite Against Tobacco as a Leading Cause of Cancer and Chronic Diseases

PNN
New Delhi [India], May 31: On the occasion of World No Tobacco Day, observed every year on May 31, leading healthcare experts across the country are sounding a clarion call against one of the biggest threats to global health: tobacco. Beyond awareness, experts are demanding urgent action, highlighting tobacco's devastating and far-reaching effects -- from cancer, respiratory, and cardiovascular disease to infertility and second-hand smoke exposure.
India currently faces over 37.5 lakh active cancer cases, and tobacco remains the single largest preventable cause. According to a global study published in The Lancet's eClinical Medicine, tobacco-related illnesses cause over 1.3 million cancer-related deaths annually across seven countries, including India.
"Smoking is one of the worst carcinogens in the world. Tobacco exposes the entire body, not just the lungs, to cancer-causing agents. It's linked to multiple cancers, including those of the lung, mouth, throat, esophagus, larynx, pancreas, bladder, kidney, stomach, cervix, colon, and even blood cancers like acute myeloid leukemia (AML)," said Dr. Dinesh Singh, Director and Head, Radiation Oncology, Action Cancer Hospital, Delhi.
Dr. Singh further warns about second-hand smoke, stating that even non-smokers exposed to it absorb carcinogens and face a significantly elevated cancer risk, especially for lung cancer.
"Tobacco smoke promotes chronic inflammation, triggering genetic instability and abnormal cell growth -- a key environment for cancer to develop. Nearly every organ in the body is affected," he explained.
Dr. Pritpal Kaur, Pulmonologist, Apollo Spectra Hospital, Karol Bagh, Delhi said, "Tobacco is a toxic cocktail that attacks the respiratory system at every level--from inflaming the airways to permanently damaging lung tissues. COPD, asthma, lung cancer, and bronchitis are just the tip of the iceberg. Tobacco doesn't just suffocate the lungs--it wreaks havoc across the entire body. Every puff poisons not just the smoker, but everyone around them."
As India continues to battle its cancer burden, Bengaluru-based SPARSH Group of Hospitals has taken a bold step forward. On May 18, 2025, SPARSH launched its flagship 300-bed multi-speciality hospital on Hennur Road, Bengaluru, introducing its first comprehensive cancer care facility. Backed by world-class infrastructure and an expert team across 50 specialities, the hospital features 75 ICU beds and an integrated oncology program.
Dr. Vivek Shetty, Senior Consultant- Head & Neck Oncology, SPARSH Hospital, Hennur Road, Bengaluru said, "Along with lung cancer, oral cancer is also alarmingly common among people who smoke or use tobacco in other forms. There is an urgent need to increase awareness about early detection through proper screening and to encourage timely treatment."
"With our new facility at Hennur Road, we now offer best-in-class comprehensive cancer care to combat these life-threatening diseases. Our mission is to bring comprehensive cancer treatment to the doorsteps of people in Karnataka, especially Bengaluru and its neighbouring regions," added Dr. Shetty.
The hospital's approach marries precision medicine, compassion, and accessibility, making it a timely answer to Karnataka's growing cancer crisis, where 86,563 new cases are projected annually, with lung and mouth cancers comprising nearly 16% of male cancers.
Whether smoked or chewed, tobacco remains the most potent and preventable health hazard. And the consequences go beyond cancer, heart disease, stroke, reproductive disorders, and chronic lung diseases, all bear its imprint.
"Tobacco addiction is difficult but not impossible to beat. With modern therapies, counselling, and the right intent, recovery is possible. Every cigarette not smoked is a step toward healing -- not just for the smoker, but for their entire family, said Dr. Arun Kumar Verma, Senior Consultant- Oncology, Chhatrapati Shivaji Subharti Hospital, Meerut.
"From lung, oral, and throat cancers to bladder and oesophageal malignancies, tobacco is a common denominator. What's worrying is that even people exposed to secondhand smoke--like family members or co-workers-are--are at risk," warned Dr. Verma, adding,
"We must dispel the myth of 'safe usage'. There is no safe level of tobacco exposure."
Experts concluded that with early detection, structured cessation programs, and accessible treatment, outcomes can dramatically improve. But quitting tobacco should also be a top priority.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

India's advanced orthopaedic implant facility to come up at MedTech Zone
India's advanced orthopaedic implant facility to come up at MedTech Zone

New Indian Express

timean hour ago

  • New Indian Express

India's advanced orthopaedic implant facility to come up at MedTech Zone

VISAKHAPATNAM: A strategic trilateral partnership between OIC International (USA), Medi Mold (India), and AddUp, a subsidiary of France-based Fives Group, is set to establish India's most advanced orthopaedic implant manufacturing unit using 3D printing technology within the Andhra Pradesh MedTech Zone (AMTZ) in Visakhapatnam. This collaboration aims to strengthen India's capabilities in producing high-performance orthopaedic implants locally and is aligned with the Government of India's 'Make in India' and medical self-reliance initiatives. OIC International will introduce a new line of orthopaedic implants manufactured using advanced 3D additive technology. These implants are designed for both domestic and international markets and are expected to reduce post-surgical recovery time while being more cost-effective. OIC International CEO Shin Shetty stated, 'India is a key strategic market for us. Manufacturing locally through AMTZ helps us bring down costs while ensuring access to quality implants in line with India's growing surgical needs.'

Now you don't need reading glasses, new FDA-approved eye drops can sharpen near vision
Now you don't need reading glasses, new FDA-approved eye drops can sharpen near vision

Time of India

timean hour ago

  • Time of India

Now you don't need reading glasses, new FDA-approved eye drops can sharpen near vision

The US Food and Drug Administration has approved Vizz eye drops. These drops improve near vision for adults over 40. Lenz Therapeutics developed this aceclidine-based treatment. Vizz narrows the pupil, increasing focus. Clinical trials showed results within 30 minutes, lasting up to 10 hours. Common side effects include dim vision and eye irritation. Now you don't need reading glasses as FDA approves Vizz eye drops to sharpen near vision for up to 10 hours Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads The US Food and Drug Administration has approved Vizz, a once-daily prescription eye drop that can temporarily improve age-related blurry near vision, or presbyopia, for up to 10 by California-based Lenz Therapeutics , Vizz is the first FDA-approved aceclidine-based treatment for presbyopia in the United States. It is expected to be available in clinics and pharmacies starting in is a common condition affecting most adults over 40, making it harder to focus on close objects. People often rely on reading glasses or contact lenses to see clearly at close works by using aceclidine to narrow the pupil, creating a 'pinhole effect' similar to a camera lens adjustment. This increases depth of focus without blurring distance vision or causing the 'zoomed-in' effect seen with some previous late-stage clinical trials, results appeared within 30 minutes, peaked at three hours and lasted for as long as 10 hours. According to the company, 71 percent of participants could read at least three more lines on a near-vision chart without loss of distance clarity.'This FDA approval represents a disruptive paradigm shift in treatment options for millions of people who are frustrated and struggling with the inevitable age-related loss of their near vision,' said Vizz clinical investigator Marc Bloomenstein, from Schwartz Laser Eye Care Center in Scottsdale, Ariz., in a statement.'I believe this will be a welcome solution for both optometrists and ophthalmologists who will now be able to offer a highly effective and sought-after presbyopia treatment that could immediately become the standard of care, with a product profile that will meet our patients' side effects reported in trials included temporary dim vision, mild eye irritation and headaches. The FDA advises patients to avoid driving or operating heavy machinery until vision clears after using the drops and to be cautious in low-light Therapeutics says the drops will be available by prescription only.

MCH officials level fresh charges against Dr Haris
MCH officials level fresh charges against Dr Haris

New Indian Express

time4 hours ago

  • New Indian Express

MCH officials level fresh charges against Dr Haris

THIRUVANANTHAPURAM: A fresh attempt to undermine Dr Haris Chirackal's credibility has emerged, with medical college authorities levelling new allegations based on questionable inspections of the urology department head's office while he was on leave. Thiruvananthapuram Medical College principal Dr P K Jabbar claimed to have uncovered a new purchase bill for equipment that had previously been reported missing from the urology department. The principal suggested that the equipment had been purchased recently after a probe committee had identified it as missing. Dr Haris countered these findings, clarifying that the newly discovered box contained two nephroscopes, not the moscilliscope flagged by the committee. A Kochi-based medical devices company had been consulted for repairs two months ago. The service engineer returned the equipment, as it was too costly to repair, along with a delivery challan dated August 2. According to Dr Haris, the principal mistakenly identified this delivery challan as a 'bill'. The situation was further complicated by the fact that the company's engineer had incorrectly labelled the returned nephroscopes as a 'moscilliscope' on the challan. Dr Haris emphasised that the moscilliscope was never lost and expressed concerns about his office being locked with a different lock during his absence. 'I was called by someone in a top position in the department to settle the issue and make compromises. But the press meet came soon after that,' Dr Haris said. The moscilliscope is used for prostate surgery, while a nephroscope is used for treating kidney stones and detecting tumours. The press meet was held on Friday even as Dr Haris has raised concerns about attempts to frame him. Both Dr Jabbar and superintendent Dr Sunil Kumar, who briefed the media, appeared to be receiving instructions from higher authorities over the phone, giving the impression that the entire situation was orchestrated. Dr Kumar openly acknowledged the pressure he faced amid the controversy.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store